160 related articles for article (PubMed ID: 19351375)
1. Re: Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Tutar E
Pathol Int; 2009 Apr; 59(4):274; author reply 274. PubMed ID: 19351375
[No Abstract] [Full Text] [Related]
2. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Amatya VJ; Takeshima Y; Kohno H; Kushitani K; Yamada T; Morimoto C; Inai K
Histopathology; 2009 Jul; 55(1):10-9. PubMed ID: 19614762
[TBL] [Abstract][Full Text] [Related]
4. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.
Ordóñez NG
Hum Pathol; 2007 Jan; 38(1):1-16. PubMed ID: 17056092
[TBL] [Abstract][Full Text] [Related]
5. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
6. Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice.
Mohammad T; Garratt J; Torlakovic E; Gilks B; Churg A
Am J Surg Pathol; 2012 Oct; 36(10):1503-8. PubMed ID: 22982894
[TBL] [Abstract][Full Text] [Related]
7. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
8. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
[TBL] [Abstract][Full Text] [Related]
9. In search of a positive immunohistochemical marker for mesothelioma: an update.
Ordóñez NG
Adv Anat Pathol; 1998 Jan; 5(1):53-60. PubMed ID: 9868512
[No Abstract] [Full Text] [Related]
10. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma?
Müller AM; Weichert A; Müller KM
Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199
[TBL] [Abstract][Full Text] [Related]
11. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
[TBL] [Abstract][Full Text] [Related]
12. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
[TBL] [Abstract][Full Text] [Related]
13. CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma.
Pinato DJ; Nya P; Sharma R; Mauri FA
J Clin Pathol; 2013 Mar; 66(3):256-9. PubMed ID: 23087328
[TBL] [Abstract][Full Text] [Related]
14. Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma.
Ohta Y; Sasaki Y; Saito M; Kushima M; Takimoto M; Shiokawa A; Ota H
Int J Surg Pathol; 2013 Oct; 21(5):493-501. PubMed ID: 23775021
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
Clark SP; Chou ST; Martin TJ; Danks JA
J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626
[TBL] [Abstract][Full Text] [Related]
16. Pleural mesothelioma in situ and its adenocarcinoma simulator.
Bono F
Int J Surg Pathol; 2010 Dec; 18(6):519-20. PubMed ID: 21081535
[No Abstract] [Full Text] [Related]
17. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
Husain AN; Colby TV; Ordóñez NG; Allen TC; Attanoos RL; Beasley MB; Butnor KJ; Chirieac LR; Churg AM; Dacic S; Galateau-Sallé F; Gibbs A; Gown AM; Krausz T; Litzky LA; Marchevsky A; Nicholson AG; Roggli VL; Sharma AK; Travis WD; Walts AE; Wick MR
Arch Pathol Lab Med; 2018 Jan; 142(1):89-108. PubMed ID: 28686500
[TBL] [Abstract][Full Text] [Related]
19. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
20. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens.
Khayyata S; Yun S; Pasha T; Jian B; McGrath C; Yu G; Gupta P; Baloch Z
Diagn Cytopathol; 2009 Mar; 37(3):178-83. PubMed ID: 19170169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]